This study will collect real-world safety and efficacy data from Japanese relapse/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) participants treated with venetoclax.
Study Type
OBSERVATIONAL
Enrollment
4
Number of Participants With Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.
Time frame: Approximately 37 weeks
Overall Incidence of Averse Drug Reactions (ADRs) of Tumor Lysis Syndrome (TLS), Bone Marrow Suppression, and Infections
Adverse drug reactions were defined as AEs of which a causal relationship with venetoclax could not be ruled out. Overall incidence of ADRs of special interest (TLS, bone marrow suppression, and infections) will be collected.
Time frame: Approximately 37 weeks
Incidence of Adverse Drug Reactions (ADR)
Adverse drug reactions were defined as AEs of which a causal relationship with venetoclax could not be ruled out. All grades of ADRs will be collected.
Time frame: Approximately 37 weeks
Incidence of TLS According to Physician Assessment
Incidence of TLS according to physician assessment.
Time frame: Approximately 37 weeks
Incidence of TLS According to Howard Criteria
Incidence of TLS according to Howard criteria which is a classification system of TLS. Laboratory results must show two or more unusual measurements within a 24-hour period.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 239524
Nagoya, Aichi-ken, Japan
Nagoya University Hospital /ID# 225300
Nagoya, Aichi-ken, Japan
Nagoya City University Hospital /ID# 240820
Nagoya, Aichi-ken, Japan
Toyohashi Municipal Hospital /ID# 227433
Toyohashi, Aichi-ken, Japan
Akita University Hospital /ID# 228510
Akita, Akita, Japan
Chiba Aoba Municipal Hospital /ID# 224486
Chiba, Chiba, Japan
Kameda General Hospital /ID# 232142
Kamogawa-shi, Chiba, Japan
National Cancer Center Hospital East /ID# 225885
Kashiwa-shi, Chiba, Japan
Kimitsu Chuo Hospital /ID# 243748
Kisarazu-shi, Chiba, Japan
Japanese Red Cross Narita Hospital /ID# 230276
Narita-shi, Chiba, Japan
...and 92 more locations
Time frame: Approximately 37 weeks
Incidence of Bone Marrow Suppression
Incidence of bone marrow suppression including neutropenia (all grades) and febrile neutropenia.
Time frame: Approximately 37 weeks
Incidence of Infections
Incidence of infections.
Time frame: Approximately 37 weeks
Incidence of ADRs When Venetoclax is Used Concomitantly with CYP3A Inhibitors
Incidence of ADRs when venetoclax is used concomitantly with CYP3A inhibitors will be collected.
Time frame: Approximately 37 weeks
Number of Prophylactic Measures Used for TLS
Number and description of prophylactic measures used in real-world clinical practice for TLS will be collected.
Time frame: Approximately 37 weeks
Number of Monitoring Measures Used for TLS
Number and description of monitoring measures used in real-world clinical practice for TLS will be collected.
Time frame: Approximately 37 weeks
Number of Participants with Dose Modifications
Summary data will be collected for participants with dose modifications.
Time frame: Approximately 37 weeks
Number of Participants with Dose Interruptions
Summary data will be collected for participants with dose interruptions.
Time frame: Approximately 37 weeks
Number of Participants Who Discontinued Venetoclax
Summary data will be collected for participants who discontinued treatment with venetoclax.
Time frame: Approximately 37 weeks
Best Overall Response Rate (ORR)
Defined as complete response (CR), complete response with incomplete marrow recovery (CRi), partial response (PR), nodular partial response (nPR) according to physician assessment based on International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 guidelines and Japanese Society of Hematology clinical guidelines.
Time frame: Approximately 37 weeks
Time to Best Response
Time to best response according to physician assessment based on International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 guidelines and Japanese Society of Hematology clinical guidelines.
Time frame: Approximately 37 weeks